Beyond Neoantigens: Antigens Derived from Tumor Drivers as Cancer Vaccine Targets

A vaccine targeting HER2, a nonmutated but overexpressed tumor antigen, readily primed T cells for ex vivo expan-sion and adoptive transfer with minimal toxicity. This regimen led to intramolecular epitope spreading in a majority of patients and offers a treatment modality that may improve outcomes for patients with metastatic breast cancer expressing HER2.

Automated summary

A vaccine targeted at HER2 can prime T cells for ex vivo expansion and adoptive transfer with minimal toxicity. This treatment modality can lead to intramolecular epitope spreading in most patients and potentially improve outcomes for patients with metastatic HER2-positive breast cancer.